Many clinical drugs, such as celecoxib and valdecoxib (COX-2 inhibitors), have been used to alleviate hepatic steatosis or lipid accumulation in MASLD models [55,56]. The gene discussed is PTGS2; the disease is metabolic dysfunction-associated steatotic liver disease.